Weston W L, Morelli J G
Department of Dermatology, University of Colorado School of Medicine, Denver, USA.
Arch Pediatr Adolesc Med. 1997 Oct;151(10):1014-6. doi: 10.1001/archpedi.1997.02170470048009.
To examine clinical associations, evolution of the condition, and response to treatment of erythema multiforme (EM) in prepubertal children.
A retrospective case series evaluation of children younger than 13 years with EM.
Ambulatory care university hospital.
Referral patients from pediatricians serving a population of 3.2 million.
Results of treatment of each EM episode with topical acyclovir or oral acyclovir at a dose of 25 mg/kg per day and 6-month prophylaxis with oral acyclovir at a dose of 20 mg/kg per day were evaluated.
Age at EM onset, preceding illness, and number and duration of episodes during a 3-year period were recorded.
Twelve children (7 boys and 5 girls) in whom herpes simplex virus (HSV)-associated EM developed were evaluated. Preceding lesions were herpes labialis in 8 children and herpes facialis in 2 children. Two children had no obvious HSV lesion. The mean age at onset of disease was 8.1 years, and the mean time from the preceding HSV to the onset of skin lesions was 3.9 days (range, 0-11 days). Episodes of EM lasted a mean of 10.6 days. In 9 children, the EM was recurrent, with a mean of 2.6 episodes per year. All 12 children, including those with negative viral cultures for HSV or no HSV history had HSV detected in their target lesions by polymerase chain reaction amplification of DNA obtained from skin biopsy specimens. Six of 12 children were treated with oral acyclovir at a dose of 25 mg/kg per day for 1 or more individual episodes, without reduction in the episode. Three children underwent 6-month prophylaxis with oral acyclovir at a dose of 20 mg/kg per day and remained disease free during treatment. After discontinuation of the prophylactic treatment with acyclovir, 1 child relapsed at 4 months. The other 2 children had no further episodes during a 3-year period.
The HSV-associated EM is a recurrent disease that can be precipitated by sun exposure and does not progress to Stevens-Johnson syndrome. Childhood HSV-associated EM may be unresponsive to treatment with oral steroids or oral or topical acyclovir. Frequent recurrences of EM may be abrogated by prophylactic treatment with acyclovir.
研究青春期前儿童多形红斑(EM)的临床关联、病情演变及治疗反应。
对13岁以下患EM儿童进行回顾性病例系列评估。
大学附属医院门诊。
来自为320万人口服务的儿科医生转诊的患者。
评估每次EM发作采用局部用阿昔洛韦或口服阿昔洛韦(剂量为每日25mg/kg)治疗的结果,以及采用口服阿昔洛韦(剂量为每日20mg/kg)进行6个月预防治疗的结果。
记录EM发病年龄、前驱疾病以及3年内发作次数和持续时间。
对12例发生与单纯疱疹病毒(HSV)相关EM的儿童(7例男孩和5例女孩)进行了评估。8例儿童的前驱病损为唇疱疹,2例为面部疱疹。2例儿童无明显HSV病损。疾病发病的平均年龄为8.1岁,从前驱HSV感染至皮肤损害发作的平均时间为3.9天(范围0 - 11天)。EM发作平均持续10.6天。9例儿童的EM为复发性,平均每年发作2.6次。所有12例儿童,包括HSV病毒培养阴性或无HSV病史的儿童,通过对皮肤活检标本DNA进行聚合酶链反应扩增,在其靶损害中均检测到HSV。12例儿童中有6例接受口服阿昔洛韦(剂量为每日25mg/kg)治疗1次或多次发作,发作次数未减少。3例儿童接受口服阿昔洛韦(剂量为每日20mg/kg)进行6个月预防治疗,治疗期间无疾病复发。停用阿昔洛韦预防性治疗后,1例儿童在4个月时复发。另外2例儿童在3年内未再发作。
与HSV相关的EM是一种复发性疾病,可以由日晒诱发,不会进展为史蒂文斯 - 约翰逊综合征。儿童期与HSV相关的EM可能对口服类固醇或口服或局部用阿昔洛韦治疗无反应。阿昔洛韦预防性治疗可能消除EM的频繁复发。